Brief: Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
23/10/2025 13:44
Oct 23 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER MOLECULIN BIOTECH INC - ESTIMATES TRIAL COST AT $1 MILLION FROM 2026 TO 2030 Source text: ID:nGNX1pvvv7 Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM